PubMed Central, : RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2017 January; 8(1): e0003. ISSN: 2076-9172Published online 2017 January 30. doi: 10.5041/RMMJ.10278.

Table 1.

Multicenter International PRINTO and PRCSG Trials of Biologic Drugs for JIA.

Study, Ref Number	Medication	Patients (n)	Indication	Israeli Usage Protocol
Lovell et al.¹⁷	TNFα inhibitor—etanercept	69	JIA	Second line after MTX failure
Ruperto et al.³	TNFα inhibitor—infliximab	122	JIA	Second line after MTX failure
Lovell et al.⁵	TNFα inhibitor—adalimumab	171	JIA	Second line after MTX failure
Ruperto et al.⁶	Co-stimulator T cell stimulation inhibitor—abatacept	190	JIA	Second line after MTX failure and/or anti-TNF failure together with MTX
Ruperto et al.⁷	Anti-IL1—canakinumab	177	SoJIA	Third line after CS and tocilizumab failure
De Benedetti et al.⁸	Anti-IL6—tocilizumab	112	SoJIA	Second line after CS failure

CS, corticosteroids; IL1, interleukin 1; IL6, interleukin 6; JIA, juvenile idiopathic arthritis; MTX, methotrexate; SoJIA, systemic onset juvenile idiopathic arthritis; TNF, tumor necrosis factor.

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2017 January; 8(1): e0003. ISSN: 2076-9172

Published online 2017 January 30. doi: 10.5041/RMMJ.10278